{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:49:16Z","timestamp":1790851756463,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"Introduction<\/jats:title>Rivaroxaban is an anticoagulant medication that targets a key stage in the blood clotting process, preventing the formation and growth of clots. It is commonly used to prevent thrombosis or inhibit the enlargement of existing clots. Rivaroxaban functions as a Factor Xa inhibitor and is indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as reducing the risk of recurrent DVT and PE, and prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.<\/jats:p><\/jats:sec>Methods<\/jats:title>A robust, precise, and selective reversed-phase high-performance liquid chromatography (HPLC) method was developed and validated for analyzing Rivaroxaban in raw materials. Isocratic elution at a flow rate of 1\u00a0mL\/min was performed using a Thermo ODS Hypersil C18 column (4.6 \u00d7 250\u00a0mm, 5\u00a0\u00b5m) at ambient temperature. The mobile phase consisted of monobasic potassium phosphate at pH 2.9 and acetonitrile in a 70:30 (v\/v) ratio, with UV detection at 249\u00a0nm.<\/jats:p><\/jats:sec>Results<\/jats:title>Linearity was established in the concentration range of 50\u20131,000\u00a0ppm (R2<\/jats:sup> = 0.999), and the retention time for Rivaroxaban was approximately 12\u00a0min. The percentage relative standard deviation (RSD) for precision and accuracy was consistently below 2.0%, ensuring method reliability. Solution stability studies confirmed the stability of Rivaroxaban over the analysis period, as no peak loss, degradation, or additional peaks were observed between the first and last injections. Furthermore, forced degradation studies were conducted under various stress conditions, including acid and base hydrolysis, as well as hydrogen peroxide oxidation. The method successfully resolved Rivaroxaban from its degradation products, demonstrating its stability-indicating capability.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Rivaroxaban is a novel oral anticoagulant that selectively and directly inhibits factor Xa<\/jats:italic>. A method has been developed and validated for its analysis, adhering to guidelines from the International Conference on Harmonisation (ICH) and the U.S. Pharmacopeia (USP). The validation process assessed parameters such as specificity, robustness, linearity, accuracy, precision, limit of detection (LOD), and limit of quantitation (LOQ). The LOD for impurities and degradants was determined to be 0.3\u00a0ppm, while the LOQ was 1\u00a0ppm. This stability-indicating method is highly suitable for routine quality control and analytical applications in both raw materials and finished drug products, owing to its simplicity, efficiency, and robustness.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fchem.2025.1551189","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T09:06:20Z","timestamp":1745571980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Comprehensive and robust stability-indicating reversed phase high performance liquid chromatography (RP-HPLC) method for Rivaroxaban: synergistic integration of infrared spectroscopy and clinical pharmacology insights"],"prefix":"10.3389","volume":"13","author":[{"given":"Aktham","family":"Mestareehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"B1","volume-title":"Guidance for industry Q1A(R2) stability testing of new drug substances and products","year":"2003"},{"key":"B2","doi-asserted-by":"publisher","first-page":"109025","DOI":"10.1016\/j.microc.2023.109025","article-title":"Green liquid chromatographic method for simultaneous determination of metformin, linagliptin and rivaroxaban: tablet manufacturing and application to in-vitro dissolution studies","volume":"193","author":"Alam","year":"2023","journal-title":"Microchem. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1590\/S1984-82502013000200018","article-title":"RP-HPLC Method development and validation for estimation of Rivaroxaban in pharmaceutical dosage forms","volume":"49","author":"C\u0327elebier Trb","year":"2013","journal-title":"Braz. J. Pharm. Sci."},{"key":"B4","article-title":"Xarelto approval history","year":"2014"},{"key":"B5","volume-title":"Validation of chromatographic methods","year":"2004"},{"key":"B6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/jpm11040250","article-title":"Drug-drug interactions leading to adverse drug reactions with rivaroxaban: a systematic review of the literature and analysis of VigiBase","volume":"11","author":"Fernandez","year":"2021","journal-title":"J. Pers. Med."},{"key":"B7","volume-title":"Validation of analytical procedures: methodology Q2(R1)","year":"2005"},{"key":"B8","volume-title":"Xarelto (Rivaroxaban) prescription blood thinner","author":"Janssen Pharmaceuticals","year":"2011"},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"26075","DOI":"10.1021\/acsomega.4c01496","article-title":"Global gene expression profiling and bioinformatics analysis reveal downregulated biomarkers as potential indicators for hepatocellular carcinoma","volume":"9","author":"Mestareehi","year":"2024","journal-title":"ACS Omega"},{"key":"B11","doi-asserted-by":"publisher","first-page":"10299","DOI":"10.1021\/acsomega.3c07787","article-title":"Impact of protein phosphatase expressions on the prognosis of hepatocellular carcinoma patients","volume":"9","author":"Mestareehi","year":"2024","journal-title":"ACS Omega"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9979234","article-title":"Metformin increases protein phosphatase 2A activity in primary human skeletal muscle cells derived from lean healthy participants","volume":"2021","author":"Mestareehi","year":"2021","journal-title":"J. Diabetes Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"B15","volume-title":"PubChem compound summary for CID 9875401. Rivaroxaban","year":"2024"},{"key":"B16","first-page":"7","article-title":"A review on step-by-step analytical method validation","volume":"5","author":"Ravisankar","year":"2015","journal-title":"IOSR J. Pharm."},{"key":"B17","first-page":"24","article-title":"A new method and validation for analysis of rivaroxaban in formulation by RP-HPLC","volume":"1","author":"Sekhar","year":"2012","journal-title":"Narendra Devanaboyina Res Desk"},{"key":"B18","volume-title":"Development and validation of assay method for the estimation of moxifloxacin in bulk and pharmaceutical formulations by RP-HPLC2024","author":"Siraj","year":"2024"},{"key":"B19","first-page":"1225","volume-title":"The United States Pharmacopeia\u2014The National Formulary","year":"1990"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"Weitz","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"B22","doi-asserted-by":"publisher","first-page":"14999","DOI":"10.3390\/molecules190914999","article-title":"A novel synthesis of the oxazolidinone antithrombotic agent rivaroxaban","volume":"19","author":"Yuan","year":"2014","journal-title":"Molecules"}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2025.1551189\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T09:06:24Z","timestamp":1745571984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2025.1551189\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":22,"alternative-id":["10.3389\/fchem.2025.1551189"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2025.1551189","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1551189"}}